We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Nanion Launches SURFE2R 96SE

Nanion Launches SURFE2R 96SE content piece image
Credit: Nanion Technologies
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

The SURFE2R 96SE is the first instrument on the market featuring the solid supported membrane (SSM) technology for the robust and simple screening of membrane transporters and pumps in a high throughput manner. With this, the SURFE2R 96SE opens new perspectives in membrane protein screening and investigations for the pharmaceutical industry, offering a label- and radioactivity-free analysis for these difficult targets. Many of these particular proteins are involved in pathological conditions and diseases, or are involved in the transport of pharmacological agents and are of high interest for drug development, but have been difficult to screen so far. The plate-based SURFE2R 96SE addresses the requirement of the pharmaceutical industry, as its technology enables screening of these targets in a simple, cost-efficient and reliable way. Furthermore, the SURFE2R 96SE contains all necessary features for a meaningful HTS screening tool, such as fully-automated sensor preparation and assay-execution, a user-friendly interface, as well as a powerful analysis software. Additionally, Nanion Technologies supports its customers with ready-to use protocols for various experimental procedures.


“We are very excited to introduce this innovative high throughput system. A large number of difficult targets can be screened with the system such as symporters, exchangers, uniporters, ion pumps and ion channels, and we are extremely happy with the quality and resolution of the data. There is a strong need for efficient and flexible assays to study properties and interactions of those transporters in drug development. The SURFE2R 96SE enables our customers to increase their focus on this interesting target group within their drug development pipeline.” said Niels Fertig, CEO of Nanion Technologies. “With more than 15 years’ experience developing high-performance instrumentation advancing electrophysiological screening approaches, we have designed this system to offer our clients a screening platform for these specific targets in a robust manner with meaningful throughput. This introduction strengthens our position as the leading provider of electrophysiological equipment by providing customers with a truly unique platform.”